Biotech

Biotech

Cytokinetics pushes ahead with ALS drug despite negative clinical trial outcome

By Adam Feuerstein

Biotech

Scientists see hope in a rare disease drug Wall Street has all but written off

By Damian Garde

Biotech

There’s a massive new data set that aims to help artificial intelligence work better for biotech — and it’s free

By Kate Sheridan

Biotech

Biotech runs on venture capital. But not all VC models are created equal

By Kate Sheridan

The Readout LOUD

Listen: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms

By Damian Garde and Adam Feuerstein

Biotech

Launching a new gene therapy will be the biggest test yet for Novartis CEO Narasimhan

By Matthew Herper

Adam's Take

Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why

By Adam Feuerstein

Biotech

5 questions for Gilead’s rookie CEO on his Wall Street debut

By Damian Garde

Biotech

The bears and bulls are fighting over drug maker InflaRx. Here’s how to know who will come out on top

By Adam Feuerstein

Biotech

Y Combinator to fund more academic spinouts developing small-molecule drugs

By Rebecca Robbins

Biotech

For Dan Doctoroff, funding ALS research is a family matter

By Jonathan Saltzman — Boston Globe

The Readout LOUD

Listen: When scientists get mad online, for-profit cancer care, & the perils of naming a startup

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

MassBio’s push to soften state drug-price legislation produces plenty of drama

By Jon Chesto — Boston Globe

Biotech

Biogen sees no need for big changes in wake of Alzheimer’s drug setback

By Adam Feuerstein

Biotech

BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know

By Adam Feuerstein

Biotech

Gelesis aims to crack the weight-loss market with its new capsule

By Jonathan Saltzman — Boston Globe

Biotech

With real estate deal, Sanofi Genzyme boosts its bottom line in hot market

By Tim Logan

Biotech

How does Biogen move beyond its Alzheimer’s drug blowup? Listen for the clues

By Adam Feuerstein

Biotech

Disappointing trial results dim hopes for a new class of pain drugs

By Damian Garde

Biotech

Drugging the undruggable and other challenges on the road to targeting RNA with pills

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

The Readout LOUD

Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins

By Adam Feuerstein

Biotech

When a new biotech’s drug pipeline is more of a ‘hypeline’

By Kate Sheridan

Biotech

Watch this company: Turning Point Therapeutics shares pop 57% after IPO

By Matthew Herper

Biotech

How one company thinks unraveling cough can provide a new way to treat pain

By Damian Garde

Startup Goldfinch Bio signs $109 million deal with Gilead to develop treatments for kidney disease

New documents reveal Third Rock Ventures is set to launch a cancer diagnostics company

Your guide to the mounting competition among new SMA drugs

With a superstar cardiologist as its CEO, new CRISPR company targets heart disease

Cytokinetics pushes ahead with ALS drug despite negative clinical trial outcome

Scientists see hope in a rare disease drug Wall Street has all but written off

There’s a massive new data set that aims to help artificial intelligence work better for biotech — and it’s free

Biotech runs on venture capital. But not all VC models are created equal

Listen: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms

Launching a new gene therapy will be the biggest test yet for Novartis CEO Narasimhan

Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why

5 questions for Gilead’s rookie CEO on his Wall Street debut

The bears and bulls are fighting over drug maker InflaRx. Here’s how to know who will come out on top

Y Combinator to fund more academic spinouts developing small-molecule drugs

For Dan Doctoroff, funding ALS research is a family matter

Listen: When scientists get mad online, for-profit cancer care, & the perils of naming a startup

MassBio’s push to soften state drug-price legislation produces plenty of drama

Biogen sees no need for big changes in wake of Alzheimer’s drug setback

BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know

Gelesis aims to crack the weight-loss market with its new capsule

With real estate deal, Sanofi Genzyme boosts its bottom line in hot market

How does Biogen move beyond its Alzheimer’s drug blowup? Listen for the clues

Disappointing trial results dim hopes for a new class of pain drugs

Drugging the undruggable and other challenges on the road to targeting RNA with pills

Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins

When a new biotech’s drug pipeline is more of a ‘hypeline’

Watch this company: Turning Point Therapeutics shares pop 57% after IPO

How one company thinks unraveling cough can provide a new way to treat pain

Biotech

Sign up for our Daily Recap newsletter